利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2167 条记录 (耗时 0.05 秒)

    CIRCULATING TUMOR CELL DIAGNOSTICS FOR DETECTION OF NEUROENDOCRINE PROSTATE CANCER (NEPC)
    82.
    发明申请
    CIRCULATING TUMOR CELL DIAGNOSTICS FOR DETECTION OF NEUROENDOCRINE PROSTATE CANCER (NEPC) 审中-公开
    用于检测神经元前列腺癌（NEPC）的循环肿瘤细胞诊断

    公开(公告)号：US20160040245A1

    公开(公告)日：2016-02-11

    申请号：US14605809

    申请日：2015-01-26

    申请人： EPIC SCIENCES, INC.

    发明人： Ryan DITTAMORE

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N2333/4742 ,  G01N2333/70589 ,  G01N2333/723

    摘要： The present invention describes a method for detecting NEPC in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), and (b) determining presence or absence of a CTC subpopulation associated with NEPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, wherein the presence of the CTC subpopulation associated with NEPC is indicative of NEPC. In other embodiments, the biomarkers for the CTC subpopulation associated with NEPC comprise small size, absence of Androgen Receptor (AR−), and presence of nucleoli (nucleoli+). In additional embodiments, the methods of the invention further comprise molecular analysis of the CTCs.

    摘要翻译： 本发明描述了一种用于在患有前列腺癌的患者中检测NEPC的方法，包括（a）进行包括免疫荧光染色和从患者获得的血液样品中的有核细胞的形态学表征的直接分析，以检测循环肿瘤细胞（CTC）， 和（b）确定与NEPC相关的CTC亚群的存在或不存在，包括检测一组形态学和蛋白质生物标志物中每个生物标志物的可测量特征，其中与NEPC相关的CTC亚群的存在是NEPC的指示。 在其他实施方案中，与NEPC相关的CTC亚群体的生物标志物包括小尺寸，不存在雄激素受体（AR-）和存在核仁（核仁+））。 在另外的实施方案中，本发明的方法还包括CTC的分子分析。

    ANTIBODY COCKTAIL
    87.
    发明申请
    ANTIBODY COCKTAIL 有权
    抗体蛋白

    公开(公告)号：US20150301054A1

    公开(公告)日：2015-10-22

    申请号：US14693084

    申请日：2015-04-22

    申请人： DAKO DENMARK A/S

    发明人： Zhiming LIAO ,  Jeanette MUSSER

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57434 ,  G01N2333/47 ,  G01N2333/4742 ,  G01N2333/99 ,  G01N2800/52

    摘要： The present invention relates to a composition comprising at least three primary antibodies or fragments thereof, wherein the at least three antibodies or fragments thereof binds specifically to at least three different proteins, and wherein the at least three different proteins are AMCAR, CK 5/6, and HMWC. Methods for using the composition in diagnosis, prognosis, and assessing efficacy of treatment is further included as well as kits comprising said composition, and optionally, instructions of its use.

    摘要翻译： 本发明涉及包含至少三种一抗或其片段的组合物，其中所述至少三种抗体或其片段特异性结合至少三种不同的蛋白质，并且其中所述至少三种不同的蛋白质是AMCAR，CK5 / 6 ，和HMWC。 进一步包括在组合物诊断，预后和评价治疗功效中使用该组合物的方法以及包含所述组合物和任选的其使用说明书的试剂盒。

    Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
    89.
    发明授权
    Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers 有权
    针对耐药性乳腺癌和胰腺癌的异常DNA修复

    公开(公告)号：US09132120B1

    公开(公告)日：2015-09-15

    申请号：US13783785

    申请日：2013-03-04

    申请人： STC.UNM ,  University of Maryland, Baltimore

    发明人： Alan Edward Tomkinson ,  Feyruz Rassool

    IPC分类号： A61K31/4184 ,  C40B40/06 ,  A61K31/165

    CPC分类号： A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

    摘要： In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

    摘要翻译： 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。